Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia

ClinicalTrials.gov ID: NCT05273749

Public ClinicalTrials.gov record NCT05273749. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia

Study identification

NCT ID
NCT05273749
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Enrollment
457 participants

Conditions and interventions

Conditions

Interventions

  • TNX-102 SL Tablet, 5.6 mg Drug
  • Placebo SL Tablet Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 5, 2022
Primary completion
Nov 13, 2023
Completion
Nov 13, 2023
Last update posted
Jan 21, 2025

2022 – 2023

United States locations

U.S. sites
33
U.S. states
20
U.S. cities
33
Facility City State ZIP Site status
Tonix Clinical Site Phoenix Arizona 85012
Tonix Clinical Site Oceanside California 92056
Tonix Clinical Site Santa Ana California 92705
Tonix Clinical Site Temecula California 92591
Tonix Clinical Site Cromwell Connecticut 06416
Tonix Clinical Site Fort Myers Florida 33912
Tonix Clinical Site Jacksonville Florida 32256
Tonix Clinical Site Miami Lakes Florida 33016
Tonix Clinical Site Ocala Florida 34470
Tonix Clinical Site Oldsmar Florida 34677
Tonix Clinical Site Orlando Florida 32801
Tonix Clinical Site Alpharetta Georgia 30022
Tonix Clinical Site Atlanta Georgia 30329
Tonix Clinical Site Evansville Indiana 47714
Tonix Clinical Site West Des Moines Iowa 50265
Tonix Clinical Site Prairie Village Kansas 66208
Tonix Clinical Site Covington Louisiana 70433
Tonix Clinical Site New Orleans Louisiana 70115
Tonix Clinical Site Prairieville Louisiana 70769
Tonix Clinical Site Boston Massachusetts 02131
Tonix Clinical Site Gulfport Mississippi 39501
Tonix Clinical Site Albuquerque New Mexico 87109
Tonix Clinical Site Williamsville New York 14221
Tonix Clinical Site Cincinnati Ohio 45219
Tonix Clinical Site Tulsa Oklahoma 74133
Tonix Clinical Site Portland Oregon 97210
Tonix Clinical Site Charleston South Carolina 29407
Tonix Clinical Site Austin Texas 78737
Tonix Clinical Site Dallas Texas 75231
Tonix Clinical Site McKinney Texas 75070
Tonix Clinical Site Charlottesville Virginia 22911
Tonix Clinical Site Danville Virginia 24541
Tonix Clinical Site Kenosha Wisconsin 53144

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05273749, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 21, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05273749 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →